

**Jiaqi Shi, MD, PhD**  
**Clinical Associate Professor of Pathology**

Department of Pathology & Clinical Labs  
University of Michigan Medical School  
2800 Plymouth Rd, Bldg 35  
Ann Arbor, MI 48109-2800  
Phone: (734)936-6770  
Fax: (734)615-8340  
Email: jiaqis@med.umich.edu

## **Education and Training**

### **Education**

09/1988-07/1995 MD, Medicine, Hunan Medical University (Xiang-Ya School of Medicine, Central South University), Changsha, Hunan China  
09/1996-07/1999 PhD, Medical Genetics, Hunan Medical University (Xiang-Ya School of Medicine, Central South University), Changsha, Hunan China

### **PostDoctoral Training**

08/1999-06/2000 Postdoctoral Research Fellow, Pharmacophysiology, University of Arizona, Tucson, AZ  
07/2000-06/2003 Postdoctoral Research Fellow, Cancer Biology, University of Arizona, Tucson, AZ  
07/2010-06/2012 Residency, Pathology (AP/CP), University of Arizona, Tucson, AZ  
07/2012-06/2014 Residency, Pathology (AP/CP), University of Michigan, Ann Arbor, MI  
07/2014-06/2015 Fellowship, Gastrointestinal and Liver Pathology, University of Michigan, Ann Arbor, MI  
12/2014 Clinical Training, Pancreatobiliary Pathology, Emory University, Atlanta, GA

## **Certification And Licensure**

### **Certification**

2009-present ECFMG #0-749-062-6  
2014-2024 American Board of Pathology - Anatomic and Clinical Pathology #14-151

### **Licensure**

2014-2024 State of Michigan, Controlled Substance  
2014-2024 State of Michigan, DEA Registration  
2014-2024 State of Michigan, Medical License

## **Academic, Administrative, Clinical, Research and Military Appointments**

### **Academic Appointments**

07/2003-05/2009 Research Assistant Professor, University of Arizona, Tucson, AZ  
05/2009-06/2010 Assistant Professor (Tenure Track), University of Arizona, Tucson, AZ  
07/2014-06/2015 Clinical Lecturer in Gastrointestinal and Liver Pathology, University of Michigan, Ann Arbor, MI  
07/2015-08/2020 Clinical Assistant Professor of Pathology, University of Michigan, Ann Arbor, MI  
09/2020-present Clinical Associate Professor of Pathology, University of Michigan, Ann Arbor, MI

## **Clinical Interests**

- Pancreas pathology
- Gastrointestinal and hepatobiliary pathology

## **Research Interests**

- Molecular mechanisms of pancreatic tumorigenesis, progression, and metastasis

- Epigenetic regulation in pancreatic cancer
- Identification of new biomarkers and targets for diagnosis, prognosis, treatment prediction, and treatment of pancreatic neoplasms

## Grants

### Current Grants

*Real-time Transcranial Histotripsy Dose Monitoring via Acoustic Cavitation Emission (ACE) Feedback Methods*  
 Focused Ultrasound Surgery Foundation  
 Co-I without Effort (Principal Investigator: Sukovich)  
 10/2020-10/2021. \$101,698

*1 R01 CA247516-01A1: Metaplastic Tuft Cells in Pancreatic Cancer.* NIH-DHHS-US- 20-PAF00628  
 Co-I with Effort (Principal Investigator: Howard C Crawford)  
 03/2020-02/2025. \$2,441,679 (\$477,977)

*K08 CA234222: Linking epigenetic regulation and TGF- $\beta$  signaling in pancreatic cancer.* NCI- 18-PAF05139  
 Jiaqi Shi, PI  
 09/2018-08/2022. \$767,761 (\$185,886)

*R01 HL141967: Forward-viewing catheter-delivered microbubble-enhanced sonothrombolysis (FV-CAMUS).* NIH /NHLBI- 18-PAF03478  
 Other (Principal Investigator: Zhen Xu)  
 08/2018-06/2022. \$771,147 (\$122,081)

*5R01CA21121702: Novel, noninvasive, rapid tumor ablation technology using histotripsy.* NIH/NCI- 17-PAF05356  
 Co-I with Effort (Principal Investigator: Zhen Xu)  
 01/2018-12/2022. \$2,776,696 (\$509,478)

### Submitted Grants

*Histotripsy for Non-invasive Ultrasound-based Ablation of Liver Cancer* NIH-DHHS-US- 21-PAF00588  
 Co-I with Effort (Principal Investigator: Xu, Zhen)  
 01/2022-12/2026. \$12,277,117

*Targeting Stromal BCAA Metabolism in PDAC Tumors* NIH-DHHS-US- 21-PAF06455  
 Co-I with Effort (Principal Investigator: Nagrath, Deepak;Lawrence, Theodore S;Nagrath, Sunitha)  
 09/2021-08/2026. \$3,691,757

*PPARD hyperactivation accelerates mutant KRAS driven pancreatic carcinogenesis* NIH-DHHS-US- 21-PAF04434  
 Co-I with Effort (Principal Investigator: Shureiqi, Imad)  
 09/2021-08/2026. \$3,939,472

### Past Grants

*A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with Gemcitabine Plus Nab-paclitaxel as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer.*  
 Fibrogen, Inc.- 20-PAF03740  
 Co-I with Effort (Principal Investigator: Vaibhav Sahai)  
 08/2019-08/2020. \$27,090 (\$27,090)

*GI Innovation Fund: Metabolic biomarkers in cyst fluid to accurately diagnose pancreatic cystic neoplasms.*  
 University of Michigan  
 Jiaqi Shi, PI  
 08/2018-10/2019. \$50,000 (\$50,000)

*N018803: PreCOG sample analysis.* PreCOG LLC- 17-PAF07998  
 Co-I with Effort (Principal Investigator: Vaibhav Sahai)  
 07/2017-12/2017. \$28,517 (\$28,517)

*U055001: Intraductal papillary mucinous neoplasm (IPMN).* University of Michigan  
Jiaqi Shi, PI  
11/2016-11/2018. \$16,887 (\$16,887)

*Small Grants Program: Metabolic profiling of cyst fluid from patients with cystic mucinous neoplasms to guide clinical management.* Michigan Regional Comprehensive Metabolomics Research Core (MRC2)  
Jiaqi Shi, PI  
11/2016-11/2017. \$5,000 (\$5,000)

*Global REACH Partnership Development Grant.* University of Michigan  
Jiaqi Shi, PI  
08/2016-08/2017. \$10,000 (\$10,000)

*M-Cubed: Metabolic profiling of cyst fluid from patients with intraductal pancreatic mucinous neoplasm to guide clinical management.* University of Michigan  
Jiaqi Shi, PI  
10/2015-04/2017. \$60,000 (\$60,000)

*70: eIF3f as a diagnostic and prognostic biomarker for pancreatic ductal neoplasms.* University of Michigan  
Jiaqi Shi, PI  
03/2015-06/2017. \$21,221 (\$21,221)

*Research Services Agreement for Protocol PrE0204: Circulating tumor cell analysis for the PrECOG0204 clinical trial.* Celgene Corporation through a consortium with PrECOG LLC- 15-PAF01160  
Co-I with Effort (Principal Investigator: Vaibhav Sahai)  
11/2014-11/2019. \$61,517 (\$6,812)

*1R03CA158895: Translational control by eIF3f in pancreatic cancer.* NIH/NCI  
Jiaqi Shi, PI  
04/2011-03/2014. \$100,000 (\$50,000)

*Faculty Seed Grant: A novel invasive pancreatic cancer mouse model.* The Office of the VP for Research, Graduate Studies, and Economic Development  
Jiaqi Shi, PI  
09/2010-09/2011. \$10,000 (\$10,000)

*Institutional Research Grant: A novel Kras-regulated translation pathway in pancreatic cancer.* American Cancer Society  
Jiaqi Shi, PI  
07/2009-06/2010. \$22,500 (\$22,500)

*P50 CA095060: Specialized program research excellence (SPORE) in gastrointestinal cancer Career Development Award.* NIH/NCI  
Jiaqi Shi, PI  
01/2009-03/2010. \$50,000 (\$50,000)

*R03 CA133449: Role of eIF3f in pancreatic cancer.* NIH/NCI  
Jiaqi Shi, PI  
05/2008-04/2011. \$100,000 (\$50,000)

*P50 CA095060: Specialized program research excellence (SPORE) in gastrointestinal cancer Career Development Award.* NIH/NCI  
Jiaqi Shi, PI  
01/2008-01/2009. \$60,000 (\$60,000)

*P50 CA095060: Specialized program research excellence (SPORE) in gastrointestinal cancer Career Development Award.* NIH/NCI  
Jiaqi Shi, PI  
04/2006-03/2007. \$50,000 (\$50,000)

0007: *Deregulation of translation initiation by eIF3f in melanoma*. Arizona Biomedical Research Commission  
Jiaqi Shi, PI  
07/2005-06/2008. \$150,000 (\$45,455)

*Faculty Small Grants Program: Investigations of eIF3f as a tumor suppressor gene in melanoma*. Office of the VP for Research, Graduate Studies, and Economic Development  
Jiaqi Shi, PI  
05/2004-05/2005. \$10,000 (\$10,000)

T32 CA009213: *Cancer Biology Training Grant*. NIH/NCI  
Other (Principal Investigator: George Timothy Bowden)  
04/2002-03/2005. \$149,000 (\$49,652)

## Honors and Awards

### International

- |      |                                                                                                                                                                                                                                                                         |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1998 | Excellent Science and Technology Paper Award, Colby Information Center of Science and Culture, Los Angeles, CA                                                                                                                                                          |
| 2011 | Benjamin Castleman Award, United States and Canadian Academy of Pathology (USCAP) and Massachusetts General Hospital (MGH) [Given to only one pathologist each year who is younger than 40 in recognition of an outstanding contribution in human anatomical pathology] |
| 2011 | Best Abstract Award, GoPath Diagnostics/Chinese American Pathologists Association (CAPA), USCAP Annual Meeting                                                                                                                                                          |
| 2013 | Highly Commended 2013 BMA Medical Book Award for Medicine                                                                                                                                                                                                               |
| 2019 | Excellence in Reviewing for Oncology Letters                                                                                                                                                                                                                            |
| 2019 | Magna Cum Laude Three Pearls Award, SCBT-MR Annual Course                                                                                                                                                                                                               |

### National

- |      |                                                                                                                   |
|------|-------------------------------------------------------------------------------------------------------------------|
| 1998 | Second Prize, the 2nd Congress of Science and Technology in the Central District of China                         |
| 1999 | Cheung Kong Scholars Achievement Award, The Ministry of Education, PR China and Li Ka Shing Foundation, Hong Kong |
| 2003 | Bristol-Myers Squibb Oncology Scholar-in-Training Award, American Association for Cancer Research (AACR)          |

### Regional

- |      |                                                                                |
|------|--------------------------------------------------------------------------------|
| 2012 | Outstanding Abstract Award, Michigan Society of Pathologists Winter Conference |
| 2013 | Outstanding Abstract Award, Michigan Society of Pathologists Winter Conference |

### Institutional

- |           |                                                                          |
|-----------|--------------------------------------------------------------------------|
| 1989-1993 | University Scholarship, Hunan Medical University, China                  |
| 2003      | Arizona Cancer Center's Most Results Poster Award, University of Arizona |
| 2020      | Mentored Research Academy: R01 Boot Camp 2020 Program                    |

## Memberships in Professional Societies

- |              |                                                                                                  |
|--------------|--------------------------------------------------------------------------------------------------|
| 2000-2005    | Associate Member, American Association for Cancer Research (AACR)                                |
| 2003         | Member, American Society for Cell Biology                                                        |
| 2005-present | Active Member, American Association for Cancer Research (AACR)                                   |
| 2005-present | Active Member, American Association for Cancer Research (AACR) - Women in Cancer Research (WICR) |
| 2010-2012    | Member, Arizona Society of Pathologists                                                          |
| 2010-2018    | Member, American Society for Clinical Pathology (ASCP)                                           |
| 2010-2018    | Member, College of American Pathologists (CAP)                                                   |

2010-present	Member, United States and Canadian Academy of Pathology (USCAP)
2012-present	Member, Michigan Society of Pathologists (MSP)
2014-present	Member, Rodger C. Haggitt Gastrointestinal Pathology Society (GIPS)
2015-2020	Member, Hans Popper Hepatopathology Society
2016-present	Member, Pancreatobiliary Pathology Society
2021-present	Member, Arthur Purdy Stout Society

## **Editorial Positions, Boards, and Peer-Review Service**

### **Study Sections**

#### **National**

2006	Peer Review Panel Member, Department of Defense (DOD)/Congressionally Directed Medical Research Programs (CDMRP) (Ad Hoc)
2009	Peer Review Panel Member, DOD/CDMRP (Ad Hoc)

#### **Institutional**

2016	Pilot Grant Reviewer, Center for RNA Biomedicine, University of Michigan (Ad Hoc)
------	-----------------------------------------------------------------------------------

#### **Editorial Boards**

2015-present	Editor, Journal of Pathology & Epidemiology
2015-present	Editorial Board Member, Journal of Modern Human Pathology
2015-present	Editorial Board Member, Pancreas-Open Journal
2018-2021	Editorial Board Member, World Journal of Gastrointestinal Oncology
2020-present	Reviewer Board Member, Cancers
2021-present	Editorial Board Member, Modern Pathology

#### **Journal Reviewer**

2009-present	Journal of Cellular and Molecular Medicine (Ad Hoc)
2012-present	Molecular Carcinogenesis (Ad Hoc)
2014-present	Cancers (Ad Hoc)
2014-present	Virchows Archiv (Ad Hoc)
2015-present	Journal of Gastrointestinal Cancer (Ad Hoc)
2016-present	Archivum Immunologiae et Therapiae Experimentalis (Ad Hoc)
2016-present	BMC Research Notes (Ad Hoc)
2017-present	Cancer Biomarkers (Ad Hoc)
2017-present	Diseases (Ad Hoc)
2017-present	F1000 Research (Ad Hoc)
2017-present	Gastroenterology & Hepatology Open Access (Ad Hoc)
2017-present	Hepatoma Research (Ad Hoc)
2017-present	Histopathology (Ad Hoc)
2017-present	International Journal of Molecular Sciences (Ad Hoc)
2017-present	Journal of Clinical and Laboratory Medicine (Ad Hoc)
2017-present	Oncotargets and Therapy (Ad Hoc)
2017-present	Technology in Cancer Research & Treatment (Ad Hoc)
2017-present	The American Journal of Pathology (Ad Hoc)
2018-present	American Journal of Clinical Pathology (Ad Hoc)
2018-present	Clinical Medicine Insights: Pathology (Ad Hoc)
2018-present	Clinical and Experimental Gastroenterology (Ad Hoc)
2018-present	Human Pathology: Case Reports (Ad Hoc)

2018-present	Journal of Clinical Medicine (Ad Hoc)
2018-present	Journal of Gastroenterology & Hepatology Research (Ad Hoc)
2018-present	World Journal of Gastroenterology (Ad Hoc)
2019-present	Journal of Cancer Research and Clinical Oncology (Ad Hoc)
2019-present	Oncology Letters (Ad Hoc)
2020-present	JCI Insight (Ad Hoc)
2020-present	Modern Pathology (Ad Hoc)
2021-present	Epigenomics (Ad Hoc)
2021-present	Genes & Diseases (Ad Hoc)
2021-present	Journal of Pathology (Ad Hoc)

## Teaching

### Graduate Student

01/1998-01/1999	Ying Wang, MS, Hunan Medical University, Changsha, China
01/2004-01/2005	Yiqing Zhang, PhD, University of Arizona, Tucson, AZ
01/2004-01/2007	Amber Kale, PhD, University of Arizona, Tucson, AZ
01/2005-01/2009	Anupama Chandramouli, PhD, University of Arizona, Tucson, AZ
01/2007	Sara Bustamante, PhD, University of Arizona, Tucson, AZ
08/2019-06/2020	Feng Tian, MS, China Pharmaceutical University, China

### Medical Student

08/2016-06/2019	Shuang Lu, MD, Xiangya School of Medicine, Central South University, China
08/2017-09/2020	Zhujun Yi, MD, Xiangya School of Medicine, Central South University, China
08/2019-08/2021	Lin Jin, MD, Xiangya School of Medicine, Central South University, China

### Postdoctoral Fellow

01/2005-01/2006	Adriana Doldan, MD, University of Arizona, Tucson, AZ
01/2009-01/2013	Fushi Wen, PhD, University of Arizona, Tucson, AZ
01/2011-01/2012	Diana Uribe, PhD, University of Arizona, Tucson, AZ
01/2016-07/2018	Shanqiao Wei, PhD, University of Michigan, Ann Arbor, MI
09/2018-01/2020	Sivakumar Jeyarajan, PhD, University of Michigan, Ann Arbor, MI
02/2019-02/2020	Hong Kim, PhD, University of Michigan, Ann Arbor, MI

### Undergraduate Student

01/2001-01/2002	Anthony Beas, BS, University of Arizona, Tucson, AZ
01/2004-01/2005	Barb Honchak, BS, University of Arizona, Tucson, AZ
01/2008-01/2009	Neha Datta, BS, University of Arizona, Tucson, AZ
01/2009-01/2012	Alex Shen, BS, University of Arizona, Tucson, AZ
01/2010-01/2012	Andrew Choi, BS, University of Arizona, Tucson, AZ
01/2015-09/2017	Brittany Silverman, BS, University of Michigan, Ann Arbor, MI
01/2016-09/2017	Hannah Gadway, BS, University of Michigan, Ann Arbor, MI

### Visiting Scholars

01/2009-01/2010	Renyuan Zhou, MD, Fifth People's Hospital of Shanghai, Shanghai, PR China
07/2016-09/2017	Yubo Cao, MD, PhD, China Medical University, China
11/2017-10/2018	Guangling Zhang, PhD, North China University of Science and Technology, China
07/2019-07/2020	Yumei Gu, MD, Capital Medical University
10/2019-09/2020	Jing Yang, MD, MS, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, China

## Teaching Activity

### Institutional

1995	Ophthalmology, Medical Student Lectures, Hunan Medical University, China (6 total hours, 50 students)
1998-1999	Medical Genetics, Medical Student Lectures, Hunan Medical University, China (20 total hours, 200 students)
2006	Pathology 515, Graduate Student Lectures, University of Arizona (2 total hours, 20 students)
2009	CBIO 595A, Graduate Student Lectures, University of Arizona (10 total hours, 12 students)
2010	Pathology, Medical Student Lectures, University of Arizona (4-6 total hours, 60-90 students)
2011	Pathology, Medical Student Lectures, University of Arizona (8 total hours, 30 students)
2015-2016	Pathology Resident Unknown Slide Conference, University of Michigan
2015-present	Pathology Resident Morning Conference Lecture, GI, Liver, and Pancreas Pathology, University of Michigan
2015-present	In-house GI Pathology Sign Out Service, University of Michigan
2015-present	M2-M4 Medical Student Clinical Rotation on GI Pathology In-house Sign Out Service, University of Michigan
2015-present	GI Pathology Consultation Sign Out Service, University of Michigan
2016	GI Pathology, Laboratory Instructor, M1 Medical Student Lectures, University of Michigan
2016	Pathology Resident Gross Conference, University of Michigan
2016-2020	Liver Pathology, M1 Medical Student Lectures, University of Michigan
2016-present	GI Pathology Resident Board Review Slide Conference, University of Michigan
2016-present	Pancreas Pathology, M1 Medical Student Lectures, University of Michigan
2018-2020	GI Pathology board review slide conference
2020	Pathology Resident Gross Conference, University of Michigan

## Clinical Track Scholarly Contribution

### Clinician-Research Scholar (translational science, clinical research, health services research)

My academic and clinical interests have been centered on pancreatobiliary and gastrointestinal (GI) pathology. My main research focuses include: 1) discovering and identifying clinically important pathohistological and immunohistochemical characteristics of pancreatobiliary and GI diseases to improve differential diagnosis; 2) identifying novel biomarkers for diagnosis, prognosis, and treatment of malignant and premalignant pancreatic neoplasms; 3) determining the molecular mechanisms of pancreatic cancer tumorigenesis and development with a goal of identifying novel molecular markers and strategies for improving diagnosis, prognosis, and treatment. In addition, I have engaged in multiple important team science research projects in pancreatobiliary and GI neoplasms.

## Committee and Administrative Services

### Committee Services

#### International

2017-2020	Abstract Review Board, Pancreas category, USCAP, Member
2017-2020	Resident Advisory Committee, United States and Canadian Academy of Pathology (USCAP), Member
2017-2021	Journal Watch Committee, Rodger C. Haggitt Gastrointestinal Pathology Society, Member
2017-present	Grossing Working Group, Pancreatobiliary Pathology Society, Member
2018-2020	Education Committee, Pancreatobiliary Pathology Society, Member
2019-2021	Case of the Quarter Subcommittee, Pancreatobiliary Pathology Society, Chair

## **Institutional**

2000-2012	Sarver Heart Center, University of Arizona, Member
2005	Cancer Biology Program, University of Arizona, Graduate Student Interviewer
2007-2012	GI Cancer Program, Arizona Cancer Center, Full Investigator
2007	College of Medicine, University of Arizona, Medical Student Interviewer
2015-2021	Translational and Clinical Research Program, Rogel Cancer Center, Affiliate Member
2016-present	Center for RNA Biomedicine, University of Michigan, Member
2016-present	Global REACH, University of Michigan, Faculty Associate
2016-present	Pathology Education Programs Committee, University of Michigan, Member
2017-present	AP/CP Residency Program Self-Study Committee, University of Michigan, Member
2018-present	Medical Scientist Training Program (MSTP) Career Advisory Panel, University of Michigan, Member
2020-present	University of Michigan Center for Gastrointestinal Research, Full member
2021-present	Cancer Epigenetics Working Group, Member
2021-present	Rogel Cancer Center, Core member

## **Administrative Services**

### **Volunteer**

2010	Judge, Billy Lane Lauffer Middle School Science Fair, Tucson, AZ, Judge student's posters during the science fair
2019	Abstract judge, miRcore, Ann Arbor, MI, Judge students' abstracts for their 6th Annual High School Research Conference

## **Visiting Professorships and Extramural Invited Presentations**

### **Visiting Professorships**

03/2004	Phosphorylation of the f subunit of eukaryotic initiation factor 3 by cyclin dependent kinase 11 suppresses translation during apoptosis, University of California, March 2004, Davis, CA
06/2008	The role of eukaryotic initiation factor 3f in pancreatic cancer, Mercer University, June 2008, Macon, GA
12/2008	The role of the eukaryotic initiation factor 3f in pancreatic cancer, Ohio State University, December 2008, Columbus, OH
10/2014	Pancreatic neoplasms of ductal origin, Saint Louis University, Topics in Pathology Lecture Series, October 2014, Saint Louis, MO
02/2018	Resident slide conference, Ohio State University, February 2018, Columbus, OH
02/2018	Cystic mucinous neoplasms in the pancreas – questions more than answers, Ohio State University, February 2018, Columbus, OH

### **Extramural Invited Presentations**

1. Karyotyping and sorting human chromosomes by dual-parameter flow cytometry, 2nd Workshop of Flow Cytometry, December 1997, Shanghai, China
2. Phosphorylation of the f subunit of eukaryotic initiation factor 3 by cyclin dependent kinase 11 suppresses translation during apoptosis, National Laboratory of Medical Genetics, November 2005, Central South University, China
3. Novel translation control mechanisms by eIF3f - a link between translation and cancer, University of Arizona College of Medicine-Phoenix Basic Medical Sciences Seminar Series, October 2010, Phoenix, AZ
4. Ulcerative colitis versus Crohn's disease – can we ever be sure, Inflammatory Bowel Disease Workshop, November 2015, Taipei, Taiwan
5. Intraductal papillary mucinous neoplasm (IPMN) versus intraductal tubulopapillary neoplasm (ITPN) - how to differentiate these two entities, 5th International Conference and Exhibition on Pathology, May 2016, Chicago, IL



6. Resident slide conference, University of Arizona, January 2017, Tucson, AZ,
7. A clinical perspective on drug-induced pancreatic injury and the need for novel biomarkers, American College of Toxicology 38th Annual Meeting, November 2017, Palm Springs, CA
8. Update on Biliary Tumors, American Society for Clinical Pathology Annual Meeting, September 2019, Phoenix, AZ
9. A COMPASS to fight pancreatic cancer, Department of Biological Sciences Seminar Series, Michigan Technological University, March 2021, Houghton, MI

### **Other**

1. The p34<sup>cdc2</sup> related CDK11 interacts with the p47 subunit of eukaryotic initiation factor 3 during apoptosis, University of Arizona, Cancer Biology Seminar Series, December 2002, Tucson, AZ
2. Aberrant expression of eukaryotic initiation factor 3f deregulates translation and apoptosis in tumor cells, University of Arizona, Cancer Biology Seminar Series, February 2006, Tucson, AZ
3. The role of CDK11/eIF3f pathway in translation and apoptosis in melanoma, University of Arizona, College of Medicine Research Office, Frontiers in Medical Research, Cancer Research Data Blitz, September 2006, Tucson, AZ
4. Decreased eIF3f expression contributes to pancreatic cancer development, University of Arizona, Arizona Cancer Center, GI SPORE Meeting, April 2008, Tucson, AZ
5. The role of the eukaryotic initiation factor 3f in pancreatic cancer, University of Arizona, Cancer Biology Seminar Series, September 2008, Tucson, AZ
6. Decreased eIF3f expression contributes to pancreatic cancer development, University of Arizona, Arizona Cancer Center, GI SPORE Developmental Programs Retreat, September 2008, Tucson, AZ
7. Molecular pathology conference, University of Michigan, December 2012, Ann Arbor, MI
8. Hematopathology educational conference, University of Michigan, January 2014, Ann Arbor, MI
9. Implication of suspicious cytology in EUS-guided FNA for pancreatic cancer, oral platform presentation, 5th Annual Anatomic, Molecular, Hematopathology Research Day, University of Michigan, January 2014, Ann Arbor, MI
10. Rheumatology conference, University of Michigan, March 2014, Ann Arbor, MI
11. Hematopathology and Anatomic Pathology Combined Case Conference, University of Michigan, May 2015, Ann Arbor, MI
12. Case presentation, New Frontiers in Pathology Conference, October 2015, Ann Arbor, MI
13. Case presentation, New Frontiers in Pathology Conference, October 2016, Ann Arbor, MI
14. A microRNA links TGF- $\beta$  signaling pathway to histone modification, University of Michigan Center for RNA Biomedicine 2nd Annual Symposium "RNA in Precision Medicine", March 2017, Ann Arbor, MI
15. Link between epigenetics and TGF- $\beta$  signaling pathway in pancreatic cancer, Global Health Initiatives Forum, University of Michigan, September 2017, Ann Arbor, MI
16. Crosstalk between epigenetic mechanism and TGF $\beta$  signaling in pancreatic cancer, Cancer Center Grand Rounds, University of Michigan, March 2018, Ann Arbor, MI
17. Moderator, Pancreas pathology platform session, USCAP Annual Meeting, March 2018, Vancouver, Canada
18. Loss of histone modification enzyme KDM6A contributes to PDAC invasion and EMT, University of Michigan Inaugural Pancreatic Disease Retreat, June 2018, Ann Arbor, MI
19. Case presentation, New Frontiers in Pathology Conference, University of Michigan, September 2018, Ann Arbor, MI
20. An unusual papillary neoplasm, New Frontiers in Pathology Conference, University of Michigan, November 2019, Ann Arbor, MI
21. A COMPASS to fight pancreatic cancer, Basic & Translational GI Research Conference, University of Michigan, December 2020, Ann Arbor, MI

### **Seminars**

1. A COMPASS to fight pancreatic cancer, Department of Pathology Research Seminar Series, University of Michigan, December 2020, Ann Arbor, MI

## Patents

### Disclosures

01/2003	Inhibition of eukaryotic initiation Factor 3 complex by eIF3 p47 – implication for anticancer drug, UA03-085, Co-inventor, Submitted on 01/2003
01/2006	Mitochondrial HSP-70 is a potential target for new cancer therapies, UA06-004, Co-inventor, Submitted on 01/2006
01/2008	Small molecule hnRNP K inhibitors, UA08-001, Inventor, Submitted on 01/2008
01/2011	Pancreatic cancer marker, UA11-094, Co-inventor, Submitted on 01/2011
01/2020	Targeting activin pathway to treat pancreatic cancer, UM OTT #2020-256, Inventor, Submitted on 01/2020
12/2016	Metabolite biomarkers for the differential diagnosis of pancreatic cystic lesions, UM OTT #7338, Inventor, Submitted on 12/2016

## Bibliography

### Peer-Reviewed Journals and Publications

1. **Shi J**, Liu SZ, Wang CY, et al: Comments on the diagnostic value of the fogging method and mydriatic method of Tropicamide to diagnose teen-agers' pseudomyopia. *Chinese Journal of Practical Ophthalmology* 15(1): 36-39, 1997.
2. **Shi J**, Tang DS, Xia JH: Purification of human metaphase chromosomes by sucrose gradient centrifugation. *Hereditas* 19(6): 25-26, 1997.
3. Zhang G, Duan C, **Shi J**, Leng A: Neoplasm inhibiting effect and sensitivity-promoting effect of indomethacin in vitro. *Hunan Yi Ke Da Xue Xue Bao* 22(6): 478-482, 1997. PM10072983
4. **Shi J**, Tang DS, Xia JH, et al: Karyotyping and sorting human chromosomes by dual-parameter flow cytometry. *Acta Laser Biology Sinica* 7(2): 100-102, 1998.
5. **Shi J**, Xia JH: Strategies of gene targeting in eukaryote. *Life Science Research* 3(2): 96-101, 1999.
6. Fan XG, **Shi J**, Liu WE, et al: Identification of lymphocytic apoptosis in HBV patients. *Chin J Intern Med* 38(2): 128, 1999.
7. Yang B, Larson DF, Beischel J, Kelly R, **Shi J**, Watson RR: Validation of conductance catheter system for quantification of murine pressure-volume loops. *J Invest Surg* 14(6): 341-355, 2001. PM11905502
8. **Shi J**, Larson DF, Yang B, Hunter K, Gorman M, Montes S, Beischel J, Watson RR: Differential effects of acute ethanol treatment on cardiac contractile function in young adult and senescent mice. *Alcohol* 24(3): 197-204, 2001. PM11557305
9. Larson DF, Yang B, **Shi J**, Gorman M, Watson RR: Senescent ventricular dysfunction: Issues related to cardiopulmonary bypass. *J Extra Corpor Technol* 32(3): 142-147, 2001. PM11146958
10. Feng Y, **Shi J**, Goldstein AM, Tucker MA, Nelson MA: Analysis of mutations and identification of several polymorphisms in the putative promoter region of the P34CDC2-related CDC2L1 gene located at 1P36 in melanoma cell lines and melanoma families. *Int J Cancer* 99(6): 834-838, 2002. PM12115485
11. Zhang J, Liu Y, **Shi J**, Larson DF, Watson RR: Side-stream cigarette smoke induces dose-response in systemic inflammatory cytokine production and oxidative stress. *Exp Biol Med* 227(9): 823-829, 2002. PM12324664
12. Tang D, **Shi J**, Tian Y, Gu W: Multiple site gene targeting in somatic cells and desired site integration of genes. *J Foshan University* 20(2): 64-68, 2002.
13. **Shi J**, Feng Y, Goulet AC, Vaillancourt RR, Sachs NA, Hershey JW, Nelson MA: The p34cdc2-related cyclin-dependent kinase 11 interacts with the p47 subunit of eukaryotic initiation factor 3 during apoptosis. *J Biol Chem* 278(7): 5062-5071, 2003. PM12446680
14. Mikolajczyk M\*, **Shi J**\*, Vaillancourt RR, Sachs NA, Nelson M (**\*equal contribution**): The cyclin-dependent kinase 11<sup>p46</sup> isoform interacts with RanBPM. *Biochem Biophys Res Commun* 310(1): 14-18, 2003. PM14511641
15. Baruch AC, **Shi J**, Feng Y, Nelson MA: New developments in the staging of melanoma. *Cancer Invest* 23(6): 561-7, 2005. PM16203664

16. Brunkhorst A, Karlén M, **Shi J**, Mikolajczyk M, Nelson MA, Metsis M, Hermanson O: A specific role for the TFIIID subunit TAF4 and RanBPM in neural progenitor differentiation. *Mol Cell Neurosci* 29(2): 250-258, 2005. PM15911349
17. **Shi J**, Nelson MA: The cyclin-dependent kinase 11 interacts with NOT2. *Biochem Biophys Res Commun* 334(4): 1310-1316, 2005. PM16039607
18. Feng Y, Ariza ME, Goulet AC, **Shi J**, Nelson MA: Death-signal-induced relocalization of cyclin-dependent kinase 11 to mitochondria. *Biochem J* 392(Pt 1): 65-73, 2005. PM16004605
19. **Shi J**, Kahle A, Hershey JW, Honchak BM, Warneke JA, Leong SP, Nelson MA: Decreased expression of eukaryotic initiation factor 3f deregulates translation and apoptosis in tumor cells. *Oncogene* 25(35): 4923-4936, 2006. PM16532022
20. Chandramouli A\*, **Shi J\***, Feng Y, Holubec H, Shanas RM, Bhattacharyya AK, Zheng W, Nelson MA (**\*equal contribution**): Haploinsufficiency of the cdc2l gene contributes to skin cancer development in mice. *Carcinogenesis* 28(9): 2028-2035, 2007. PM17389615
21. Doldan A, Chandramouli A, Shanas R, Bhattacharyya A, Cunningham JT, Nelson MA, **Shi J**: Loss of the eukaryotic initiation factor 3f in pancreatic cancer. *Mol Carcinogenesis* 47(3): 235-244, 2008. PM17918192
22. Doldan A, Chandramouli A, Shanas R, Bhattacharyya A, Leong SP, Nelson MA, **Shi J**: Loss of the eukaryotic initiation factor 3f in melanoma. *Mol Carcinogenesis* 47(10): 806-813, 2008. PM18381585
23. **Shi J**, Hershey JW, Nelson MA: Phosphorylation of the eukaryotic initiation factor 3f by cyclin-dependent kinase 11 during apoptosis. *FEBS Lett* 583(6): 971-977, 2009. PM19245811
24. Zhou R, Shanas R, Nelson MA, Bhattacharyya A, **Shi J**: Increased expression of the heterogeneous nuclear ribonucleoprotein K in pancreatic cancer and its association with the mutant p53. (**chosen as cover**) *Int J Cancer* 126(2): 395-404, 2010. PM19609950
25. Wen F, Shen A, Shanas R, Bhattacharyya A, Lian F, Hostetter G, **Shi J**: Higher expression of the heterogeneous nuclear ribonucleoprotein K in melanoma. *Ann Surg Oncol* 17(10): 2619-2627, 2010. PM20499280
26. Zhou R, Shen A, **Shi J**: The eukaryotic initiation factor 3 and cancer. *Current Topics in Biochemical Research* 12(1): 9-15, 2010.
27. Wen F, Zhou R, Shen A, Choi A, Uribe D, **Shi J**: The tumor suppressive role of eIF3f and its function in translation inhibition and rRNA degradation. *PLoS One* 7(3): e34194, 2012. PM22457825
28. Wen F, Shen A, Choi A, Gerner EW, **Shi J**: Extracellular DNA in pancreatic cancer promotes cell invasion and metastasis. *Cancer Res* 73(14): 4256-4266, 2013. PM23722544
29. **Shi J**, Lew M, Zalupski MM, Roh MH, Kwon RS, Pang JC: Implication of suspicious cytology in endoscopic ultrasound-guided fine-needle aspiration for pancreatic cancer. *J Gastrointest Cancer* 46(1): 54-59, 2015. PM25576465
30. **Shi J**, McKenna BJ: Cytomegalovirus-induced inflammatory pseudotumour. *Pathology* 48(7): 750-752, 2016. PM27956276
31. Rooney SL, **Shi J**: Intraductal tubulopapillary neoplasm of the pancreas - an update from a pathologist's perspective. *Arch Pathol Lab Med* 140(10): 1068-1073, 2016. PM27684978
32. Silverman BR, **Shi J**: Alterations of epigenetic regulators in pancreatic cancer and their clinical implications. *Int J Mol Sci* 17(12): 2138, 2016. PM27999365
33. Pei X, Zhu J, Yang R, Tan Z, An M, **Shi J**, Lubman DM: CD90 and CD24 co-expression is associated with pancreatic intraepithelial neoplasias. *PLoS One* 11(6): e0158021, 2016. PM27332878
34. **Shi J**: Unusual Gastric Nodules. *Gastroenterology* 151(3): e13-14, 2016. PM27490229
35. Vlasisavljevich E, Greve J, Cheng X, Ives K, **Shi J**, Jin L, Arvidson A, Hall T, Welling TH, Owens G, Roberts W, Xu Z: Non-Invasive Ultrasound Liver Ablation Using Histotripsy: Chronic Study in an In Vivo Rodent Model. *Ultrasound Med Biol* 42(8): 1890-1902, 2016. PM27140521/PMC4912895
36. Stidham RW, Wu J, **Shi J**, Lubman DM, Higgins PD: Serum glycoproteome profiles for distinguishing intestinal fibrosis from inflammation in Crohn's disease. *PLoS ONE* 12(1): e0170506, 2017. PM28114331
37. Zhu J, Wu J, Pei X, Tan Z, **Shi J**, Lubman DM: Annexin A10 is a candidate marker associated with the progression of pancreatic precursor lesions to adenocarcinoma. *PLoS ONE* 12(4): e0175039, 2017. PM28369074

38. Reid MD, Muraki T, HooKim K, Memis B, Graham RP, Allende D, **Shi J**, Schaeffer DF, Singh R, Basturk O, Adsay V: Cytologic features and clinical implications of undifferentiated carcinoma with osteoclastic giant cells of the pancreas: An analysis of 15 cases. *Cancer Cytopathol* 125(7): 563-575, 2017. PM28371566
39. Hawes SN, **Shi J**: Gastric perineurioma: clinicopathological characteristics. *Pathology* 49(4): 444-447, 2017. PM28438389
40. Zhang X, Macoskey JJ, Ives K, Owens GE, Gurm HS, **Shi J**, Pizzuto M, Cain CA, Xu Z: Non-Invasive Thrombolysis Using Microtripsy in a Porcine Deep Vein Thrombosis Model. *Ultrasound Med Biol* 43(7): 1378-1390, 2017. PM28457630/PMC5440202
41. Allen SP, Vlaisavljevich E, **Shi J**, Hernandez-Garcia L, Cain CA, Xu Z, Hall TL: The response of MRI contrast parameters in in vitro tissues and tissue mimicking phantoms to fractionation by histotripsy. *Phys Med Biol* 62(17): 7167-7180, 2017. PM28741596
42. Schechter S, **Shi J**: Simple Mucinous Cyst of the Pancreas: Review and Update. *Arch Pathol Lab Med* 141(10): 1330-1335, 2017. PM28968161
43. Lundt JE, Allen SP, **Shi J**, Hall TL, Cain CA, Xu Z: Non-invasive, Rapid Ablation of Tissue Volume Using Histotripsy. *Ultrasound Med Biol* 43(12): 2834-2847, 2017. PM28935135/PMC5693635
44. Schofield HK, Tandon M, Park MJ, Halbrook CJ, Ramakrishnan SK, Kim EC, **Shi J**, Omary MB, Shah YM, Esni F, Pasca di Magliano M: Pancreatic HIF2 $\alpha$  Stabilization Leads to Chronic Pancreatitis and Predisposes to Mucinous Cystic Neoplasm. *Cell Mol Gastroenterol Hepatol* 5(2): 169-185.e2, 2017. PM29693047/PMC5904051
45. Macoskey JJ, Zhang X, Hall TL, **Shi J**, Beig SA, Johnsen E, Lee FT Jr., Cain CA, Xu Z: Bubble-Induced Color Doppler Feedback Correlates with Histotripsy-Induced Destruction of Structural Components in Liver Tissue. *Ultrasound Med Biol* 44(3): 602-612, 2018. PM29329687/PMC5801099
46. Abel EV, Goto M, Magnuson B, Abraham S, Ramanathan N, Hotaling E, Alaniz AA, Kumar-Sinha C, Dziubinski ML, Urs S, Wang L, **Shi J**, Waghay M, Ljungman M, Crawford HC, Simeone DM: HNF1A is a novel oncogene that regulates human pancreatic cancer stem cell properties. *Elife* 7: e33947, 2018. PM30074477/PMC6122955
47. Lazarus J, Maj T, Smith JJ, Perusina Lanfranca M, Rao A, D'Angelica MI, Delrosario L, Girgis A, Schukow C, Shia J, Kryczek I, **Shi J**, Wasserman I, Crawford H, Nathan H, Pasca Di Magliano M, Zou W, Frankel TL: Spatial and phenotypic immune profiling of metastatic colon cancer. *JCI Insight* 3(22): e121932, 2018. PM30429368
48. D'Amico S, **Shi J**, Martin BL, Crawford HC, Petrenko O, Reich NC: STAT3 is a master regulator of epithelial identity and KRAS-driven tumorigenesis. *Genes Dev* 32(17-18): 1175-1187, 2018. PM30135074 /PMC6120712
49. Zeinali M, Murlidhar V, Fouladdel S, Hafner M, Shao S, Zhao L, Cameron H, Bankhead A III, **Shi J**, Cuneo KC, Sahai V, Azizi E, Wicha MS, Hafner M, Simeone DM, Nagrath S: Profiling heterogeneous circulating tumor cells (CTC) populations in pancreatic cancer using a serial microfluidic CTC Carpet Chip. *Adv Biosyst* 2: 1800228. doi: 10.1002/adbi.201800228, 2018.
50. Halbrook CJ, Pontious C, Kovalenko I, Lapienyte L, Dreyer S, Lee HJ, Thurston G, Zhang Y, Lazarus J, Sajjakulnukit P, Hong HS, Kremer DM, Nelson BS, Kemp S, Zhang L, Chang D, Biankin A, **Shi J**, Frankel TL, Crawford HC, Morton JP, Pasca di Magliano M, Lyssiotis CA: Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer. *Cell Metab* 29(6): 1390-1399, 2019. PM30827862
51. Lazarus J, Akiska Y, Lanfranca MP, Delrosario L, Sun L, Long D, **Shi J**, Crawford H, Pasca Di Magliano M, Zou W, Frankel TL: Optimization, design and avoiding pitfalls in manual multiplex fluorescent immunohistochemistry. *J Vis Exp* 149: e59915, 2019.
52. Ettel M, Zhao L, Schechter S, **Shi J**: Expression and prognostic value of NSD1 and SETD2 in pancreatic ductal adenocarcinoma and its precursor lesions. *Pathology* 51(4): 392-398, 2019. PM31060750
53. Zhang Q, Green MD, Lang X, Lazarus J, Parsels J, Wei S, Parsels LA, **Shi J**, Ramnath N, Wahl DR, Pasca di Magliano M, Frankel TL, Kryczek I, Lei Y, Lawrence TS, Zou W, Morgan MA: Inhibition of ATM increases interferon signaling and sensitizes pancreatic cancer to immune checkpoint blockade therapy. *Cancer Res* 79(15): 3940-3951, 2019. PM31101760
54. Lazarus J, Oneka MD, Barua S, Maj T, Lanfranca MP, Delrosario L, Sun L, Smith JJ, D'Angelica MI, Shia J, Fang JM, **Shi J**, Di Magliano MP, Zou W, Rao A, Frankel TL: Mathematical Modeling of the Metastatic Colorectal Cancer Microenvironment Defines the Importance of Cytotoxic Lymphocyte Infiltration and Presence of PD-L1 on Antigen Presenting Cells. *Ann Surg Oncol* 26(9): 2821-2830, 2019. PM31250346

55. Fang JM, **Shi J**: A Clinicopathologic and Molecular Update of Pancreatic Neuroendocrine Neoplasms With a Focus on the New World Health Organization Classification. *Arch Pathol Lab Med* 143(11): 1317-1326, 2019. PM31509453
56. **Shi J**, Basturk O: Whipple Grossing in the Era of New Staging: Should We Standardize? *Diagnostics (Basel)* 9(4): 132, 2019. PM31569496
57. Bhattarai S, Graham RP, Sigel CS, **Shi J**, Gonzalez RS, Xue Y, Krasinskas AM, HooKim K, Adsay V, Reid MD: Bile duct involvement by hepatocellular carcinoma: A rare occurrence and poor prognostic indicator in bile duct brushing samples. *Cancer Cytopathol* 127(11): 691-699, 2019. PM31518056
58. Reid MD, Bhattarai S, Graham RP, Pehlivanoglu B, Sigel CS, **Shi J**, Saqi A, Shirazi M, Xue Y, Basturk O, Adsay V: Pancreatoblastoma: Cytologic and histologic analysis of 12 adult cases reveals helpful criteria in their diagnosis and distinction from common mimics. *Cancer Cytopathol* 127(11): 708-719, 2019. PM31581358
59. Tran NH, Sahai V, Griffith KA, Nathan H, Kaza R, Cuneo KC, **Shi J**, Kim E, Sonnenday CJ, Cho CS, Lawrence TS, Zalupski MM: Phase II trial of neoadjuvant FOLFIRINOX and IMRT concurrent with FDR-gemcitabine in patients with borderline resectable pancreatic cancer. *Int J Radiat Oncol Biol Phys* 106(1): 124-133, 2020. PM31494181
60. Perusina Lanfranca M, Zhang Y, Girgis A, Kasselmann S, Lazarus J, Kryczek I, Delrosario L, Rhim A, Koneva L, Sartor M, Sun L, Halbrook C, Nathan H, **Shi J**, Crawford HC, Pasca di Magliano M, Zou W, Frankel TL: Interleukin 22 Signaling Regulates Acinar Cell Plasticity to Promote Pancreatic Tumor Development in Mice. *Gastroenterology* 158(5): 1417-1432.e11, 2020. PM31843590
61. Aslam A, Wasnik AP, **Shi J**, Sahai V, Mendiratta-Lala M: Intraductal papillary neoplasm of the bile duct (IPNB): CT and MRI appearance with radiology-pathology correlation. *Clin Imaging* 66: 10-17, 2020. PM32438236
62. Shankar S, Tien JC, Siebenaler RF, Chugh S, Dommeti VL, Zelenka-Wang S, Wang XM, Apel IJ, Waninger J, Eyunni S, Xu A, Mody M, Goodrum A, Zhang Y, Tesmer JJ, Mannan R, Cao X, Vats P, Pitchaiya S, Ellison SJ, **Shi J**, Kumar-Sinha C, Crawford HC, Chinnaiyan AM: An essential role for Argonaute 2 in EGFR-KRAS signaling in pancreatic cancer development. *Nat Commun* 11(1): 2817, 2020. PM32499547/PMC7272436
63. Zhu Z, Achreja A, Meurs N, Animasahun O, Owen S, Mittal A, Parikh P, Lo TW, Franco-Barraza J, **Shi J**, Gunchick V, Sherman MH, Cukierman E, Pickering AM, Maitra A, Sahai V, Morgan MA, Nagrath S, Lawrence TS, Nagrath D: Tumour-reprogrammed stromal BCAT1 fuels branched-chain ketoacid dependency in stromal-rich PDAC tumours. *Nat Metab* 2(8): 775-792, 2020. PM32694827/PMC7438275
64. Lee SY, Pakela JM, Na K, **Shi J**, McKenna BJ, Simeone DM, Yoon E, Scheiman JM, Mycek MA: Needle-compatible miniaturized optoelectronic sensor for pancreatic cancer detection. *Sci Adv* 6(47): eabc1746, 2020. PM33219025/PMC7679167
65. Worlikar T, Mendiratta-Lala M, Vlaisavljevich E, Hubbard R, **Shi J**, Hall T, Cho CS, Lee FT, Greve J, Xu Z: Effects of histotripsy on local tumor progression in an in vivo orthotopic rodent liver tumor Model. *BME Frontiers* 2020: 9830304, 2020.
66. Azizi N, Toma J, Martin M, Khalid MF, Mousavi F, Win PW, Borrello MT, Steele N, **Shi J**, di Magliano MP, Pin CL: Loss of activating transcription factor 3 prevents KRAS-mediated pancreatic cancer. *Oncogene* 40(17): 3118-3135, 2021. PM33864001
67. Dhall D\*, **Shi J**\*, Allende DS, Jang KT, Basturk O, Adsay V, Kim GE (\*both authors contributed equally): Towards a More Standardized Approach to Pathologic Reporting of Pancreatoduodenectomy Specimens for Pancreatic Ductal Adenocarcinoma: Cross-continental and Cross-specialty Survey From the Pancreatobiliary Pathology Society Grossing Working Group. *Am J Surg Pathol* Apr 23: doi: 10.1097/PAS.0000000000001723., 2021. PM33899790

## Non-Peer-Reviewed Journals and Publications

1. **Shi J**, Nelson MA: EIF3F (eukaryotic translation initiation factor 3, subunit F). *Atlas Genet Cytogenet Oncol Haematol* 14(6): 550-551, 2010.
2. **Shi J**: Epigenetic alterations in pancreatic cancer. *Pancreas Open J* 1: e5-7, 2016.
3. Schechter S and **Shi J**: Intraductal tubulopapillary neoplasm of the pancreas. *Clinical Laboratory International* September: 6-9, 2017.
4. **Shi J**: Referee Report for: Case Report: Inflammatory myofibroblastic tumor causes formation of an ileal conglomerate in a patient previously treated for Wilms' tumor. *F1000Research* 6: 677, 2017.

- Lu S, Kim HS, Cao Y, Bedi K, Chain K, Zhao L, Narayanan IV, Yi Z, Yang J, Gu Y, Paulsen MT, Ljungman M, Jeyarajan S, Thomas D, Dou Y, Crawford H, Pasca di Magliano M, **Shi J**: KMT2D links TGF- $\beta$  signaling to non-canonical activin pathway and regulates pancreatic cancer cell plasticity. *bioRxiv* 04.02.012138: doi: <https://doi.org/10.1101/2020.04.02.012138>, 2020.
- Azizi N, Toma J, Martin M, Khalid MF, Steele N, **Shi J**, Pasca di Magliano M, Pin CL: Loss of Activating Transcription Factor 3 prevents KRAS-mediated pancreatic cancer. *bioRxiv* 2020.03.27.011601: doi: <https://doi.org/10.1101/2020.03.27.011601>, 2020.

## Book Chapters

- Zhao Y, **Shi J**, et al: Tea pigment induced HL-60 apoptosis and its impact on cell cycle. Collection of clinical researches on tea pigment, Zhao Y, Shi J, et al (Eds.) Chinese Medical Science and Technology Publishing House, 1998. 975-977
- Shi J**, Feng Y, Drouse RS, Leong S, Nelson MA: Molecular Therapeutics of Melanoma. Genomic and Personalized Medicine, Ginsburg G, Willard H (Eds.) Academic Press, 2008. 1st, 80, 967-976

## Other Media

### Editorial comment

- Boyle KA, Dwinell MB: GEMMs are a gem when it comes to defining the role of HIF2 $\alpha$  in mucinous cystic neoplasms, *Cell Mol Gastroenterol Hepatol*, 2017.
- Pylayeva-Gupta Y: Pancreatic cancer thrives on hijacking a homeostatic tissue repair pathway, *Gastroenterology*, 2020.

### Provider educational material

- Ettel M, **Shi J**: Gastrointestinal Pathology Society (GIPS) Case of the month, Gastrointestinal Pathology Society (GIPS), 2018.
- Mowers J, and **Shi J**: Pancreatobiliary Pathology Society (PBPS) Case of the Quarter, Pancreatobiliary Pathology Society (PBPS), 2018.
- Kitson A, **Shi J**: Simple mucinous cyst, PathologyOutlines.com, 2020.

## Abstracts

- Yang B, Larson DF, **Shi J**, Gorman MD, Watson RR (**poster presentation**): Modification of iNOS activity in senescent cardiac dysfunction, *Suppl Circulation*, 104, 17, 2063, 2001.
- Yang B, Larson DF, **Shi J**, Zhang J, Watson RR (**poster presentation**): Tumor necrosis factor (TNF) acutely depresses myocardial contractility and relaxation via iNOS independent pathway, FASEB, New Orleans, LA, 2002.
- Shi J**, Feng Y, Goulet A, Vaillancourt R, Sachs N, Hershey J, Nelson M (**poster presentation**): The cyclin dependent kinase family member PITSLRE p110 interacts with the p47 subunit of eukaryotic initiation factor 3 during apoptosis, The Annual Meeting of the ASCB, San Francisco, CA, *Mol Biol Cell*, 13, supplement, 164a, 2002.
- Beas A, **Shi J**, Sargent L, Nelson M (**poster presentation**): The transcription factor, E2F1, is overexpressed in malignant melanoma, Thirteenth Annual Undergraduate Biology Research Conference, Tucson, AZ, 2002.
- Shi J**, Feng Y, Goulet A-C, Vaillancourt RR, Sachs NA, Hershey JW, Nelson MA (**poster presentation**): The p34cdc2 related CDK11 interacts with the p47 subunit of eukaryotic initiation factor 3 during apoptosis, AACR Annual Meeting, Washington, DC, *Proceedings of the American Association for Cancer Research*, 44, 1367, 2003.
- Shi J**, Hershey JWB, Honchak BM, Nelson MA (**poster presentation**): Phosphorylation by cyclin-dependent kinase 11 enhances the translational inhibitory function of the f subunit of eukaryotic initiation factor 3 during apoptosis, Second International Melanoma Research Congress, Phoenix, AZ, 2004.
- Shi J**, Honchak BM, Hershey JWB, Nelson MA (**poster presentation**): Aberrant expression of eukaryotic initiation factor 3f in melanoma, AACR, Los Angeles, CA, *Cancer Res*, 46, 9 Suppl, Abstr Nr 2889, 2005.
- Kahle AC, **Shi J**, Nelson MA (**poster presentation**): Elucidation of the role of cyclin dependent kinase 11 p<sup>58</sup> in mitosis, AACR, Los Angeles, CA, *Cancer Res*, 46, 9 Suppl, Abstr Nr 4434, 2005.

9. Doldan A, Bhattacharyya A, Cunningham JT, Sargent L, **Shi J**, Nelson MA (**poster presentation**): Loss of eIF3f in pancreatic cancer, 14<sup>th</sup> SPORE Investigators' Workshop, Tucson, AZ, 2006.
10. **Shi J**, Hershey JWB, Nelson MA (**poster presentation**): Phosphorylation by cyclin-dependent kinase 11 enhances the translational inhibitory function of the f subunit of eukaryotic initiation factor 3 during apoptosis, AACR Annual Meeting, Washington, DC, *Cancer Res*, 66, 8 Suppl, Abstr Nr 2462, 2006.
11. **Shi J**, Datta N, Chandramouli A, Bhattacharyya A (**poster presentation**): eIF3f, a novel tumor suppressor in pancreatic cancer, AHSC Frontiers in Biomedical Research Poster Forum, Tucson, AZ, 2008.
12. **Shi J**, Datta N, Chandramouli A, Bhattacharyya A (**poster presentation**): The tumor suppressive role of eIF3f in pancreatic cancer, AACR Annual Meeting, Denver, CO, *Cancer Res*, 69, 9 Suppl, 4264, 2009.
13. **Shi J**, Datta N, Chandramouli A, Bhattacharyya A (**poster presentation**): The tumor suppressive role of eIF3f in pancreatic cancer, AHSC Frontiers in Biomedical Research Poster Forum, Tucson, AZ, 2009.
14. Wen F, **Shi J** (**poster presentation**): eIF3f- a master regulator of protein translation, AACR Special Conference – Protein Translation and Cancer, Coronado, CA, 2010.
15. Wen F, Shen A, Choi A, **Shi J** (**poster presentation**): Extracellular DNA in pancreatic cancer metastasis, AACR 102<sup>nd</sup> Annual Meeting, Orlando, FL, *Cancer Res*, 71, 8 Suppl, Abstr Nr 2421, 2011.
16. **Shi J**, Wen F, Zhou R, Shen A, Choi A, Bhattacharyya A (**poster presentation**): Identification of eIF3f as a new tumor suppressor in pancreatic cancer, USCAP Annual Meeting, San Antonio, TX, 2011.
17. Wen F, Shen A, Choi A, **Shi J** (**poster presentation**): A xenograft pancreatic cancer mouse model to study the function of extracellular DNA in metastasis, AACR Annual Meeting, Chicago, IL, *Cancer Res*, 72, 8 Suppl, Abstr Nr 1402, 2012.
18. Uribe D, Wen F, Shen A, Choi A, **Shi J** (**poster presentation**): Binding selectivity of RNAs by eukaryotic initiation factor 3f in pancreatic cells, AACR Annual Meeting, Chicago, IL, *Cancer Res*, 72, 8 Suppl, Abstr Nr LB-150, 2012.
19. **Shi J**, Wen F, Shen A, Choi A (**platform introduction and poster presentation, Outstanding Abstract Award**): Extracellular DNA contributes to pancreatic cancer invasion and metastasis, Michigan Society of Pathologists Winter Conference, Plymouth, MI, 2012.
20. **Shi J**, Wen F, Zhou R, Shen A, Choi A (**poster presentation**): Tumor suppressor eIF3f inhibits translation by regulating rRNA degradation, USCAP Annual Meeting, Vancouver, Canada, 2012.
21. **Shi J**, Lew M, Pang J (**platform introduction and poster presentation, Outstanding Abstract Award**): Implication of suspicious cytology on endoscopic ultrasound-guided fine needle aspiration for pancreatic cancer, Michigan Society of Pathologists Winter Conference, Plymouth, MI, 2013.
22. **Shi J**, Wen F, Shen A, Choi A (**poster presentation**): Extracellular DNA contributes to pancreatic cancer invasion and metastasis, USCAP Annual Meeting, Baltimore, MD, *Lab Invest*, 93, 430A-431A, Abstr #1792, 2013.
23. **Shi J**, Greenson J, Greenhawt M (**poster presentation**): Novel approaches at identifying patient phenotypes in eosinophilic esophagitis, MICHR Symposium, Ann Arbor, MI, 2014.
24. Zhang X, Macoskey JJ, Ives K, Owens GE, Gurm HS, **Shi J**, Pizzuto M, Cain CA, Xu Z (**poster presentation**): Noninvasive thrombolysis using microtripsy in a porcine deep vein thrombosis model, 5th International Symposium on Focused Ultrasound, North Bethesda, MD, 2016.
25. Pei X, Zhu J, Yang R, **Shi J**, Tan Z, An M, Lubman DM (**poster presentation**): CD90 Expression is associated with Pancreatic Intraepithelial Neoplasias, 64th ASMS Conference, San Antonio, TX, 2016.
26. Wang L, Yang H, Abel EV, Palmbos PL, Halbrook C, Takeuchi K, **Shi J**, Zhang Y, Urs S, Waghray M, Pasca di Magliano M, Rhim AD, Crawford HC, Simeone DM (**poster presentation**): ATDC is required for KRAS-induced pancreatic tumorigenesis, AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care, Orlando, FL, *Cancer Res*, 76, 24 Suppl, Abstr Nr A62, 2016.
27. **Shi J**, Silverman B, Zhao L (**poster presentation**): Altered eIF3f subcellular localization and expression in pancreatic ductal adenocarcinomas and its precursor lesions, AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care, Orlando, FL, *Cancer Res*, 76, 24 Suppl, Abstr Nr B26, 2016.
28. Vlaisavljevich E, Greve J, Cheng X, Ives K, **Shi J**, Arvidson A, Hall T, Welling T, Owens G, Roberts W, Xu Z (**platform presentation**): Non-invasive ultrasound liver ablation using histotripsy: chronic study in an in vivo rodent model, BMES Annual Meeting, Minneapolis, MN, 2016.

29. Stidham RW, Wu J, Lubman DM, Appelman HD, **Shi J**, Higgins P (**poster presentation**): Serum glycoproteome profiles for distinguishing intestinal inflammation from fibrosis in Crohn's disease, Digestive Disease Week, San Diego, CA, 2016.
30. Lazarus J, Maj T; Lanfranca MP; Delrosario L; **Shi J**; Zou W; Frankel T (**poster presentation**): Multiplex fluorescent immunohistochemistry allows for analysis of spatial distribution patterns of immune cells in cancer, 16<sup>th</sup> Annual Pathology Research Symposium, Ann Arbor, MI, 2017.
31. Shankar S, Tien J, Dommeti VL, Zelenka-Wang S, Apel IA, **Shi J**, Kumar-Sinha C, Chinnaiyan AM (**platform presentation**): An in vivo role for Argonaute 2 in KRAS driven pancreatic cancer, AACR Annual Meeting, Washington, DC, *Cancer Research*, 77, 13 Suppl, Abstr Nr 3029, 2017.
32. Zhu J, Wu J, Pei X, Tan Z, An M, **Shi J**, Lubman DM (**poster presentation**): Annexin A10 is a candidate marker associated with the progression of pancreatic precursor lesions to adenocarcinoma, ASMS Annual Conference, Indianapolis, IN, 2017.
33. Reid MD, HooKim K, Muraki T, Memis B, Graham R, **Shi J**, Allende D, Schaeffer D, Adsay V (**poster presentation**): Cytologic features of undifferentiated carcinoma with osteoclast-like giant cells (U-OGCa) of pancreas; a multi-institutional clinicopathologic review of 14 cases, The USCAP Annual Meeting, San Antonio, TX, 2017.
34. Lin J, Snover DC, Odze RD, Liu X, Lee H, Westerhoff M, Hammer STG, Nalbantoglu I, Cummings OW, Wang H, McKenna BJ, Owen SR, McHugh JB, Saxena R, **Shi J**, Choi EYK, Esnakula A, Kresak JL, Goldblum JK, Appelman HD, Rex DK (**platform presentation**): Does serrated polyp unclassified exist? A nationwide study and survey, The USCAP Annual Meeting, San Antonio, TX, 2017.
35. Schechter S, Silverman B, Zhao L, **Shi J** (**poster presentation**): Expression and subcellular localization of eukaryotic initiation factor 3 subunit f (eIF3f) is altered in pancreatic ductal adenocarcinoma (PDA) and its precursor lesions, The USCAP Annual Meeting, San Antonio, TX, 2017.
36. Yi Z, Wei S, Lu S, Paulsen M, Bedi K, Ljungman M, **Shi J** (**poster presentation**): Loss of KDM6A upregulates EMT and activin signaling and promotes cell migration/ invasion in pancreatic ductal adenocarcinoma, AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care, Boston, MA, 2018.
37. Lu S, Cao Y, Zhang G, Bedi K, Paulsen M, Ljungman M, **Shi J** (**poster presentation**): Crosstalk between KMT2D and TGF- $\beta$  signaling in pancreatic cancer, Rogel Cancer Center Spring Symposium, Ann Arbor, MI, 2018.
38. Yi Z, Wei S, Lu S, Paulsen M, Bedi K, Ljungman M, **Shi J** (**poster presentation**): Role of KDM6A in pancreatic ductal adenocarcinoma metastasis, Rogel Cancer Center Spring Symposium, Ann Arbor, MI, 2018.
39. Macoskey J, Zhang X, Hall T, **Shi J**, Vlaisavljevich E, Lee F, Cain C, Xu Z (**platform presentation**): Histological correlation of histotripsy-induced tissue destruction with acoustic-based feedback, SIR Annual Scientific Meeting, Los Angeles, CA, *J Vasc Interv Radiol*, 29, 4, S169, 2018.
40. Shankar S, Tien J, Siebenaler RF, Dommeti VL, Zelenka-Wang S, Juckette KM, Xu A, Mody M, Goodrum A, Tsaloff G, Apel IJ, Wang L, Siddiqui J, **Shi J**, Kumar-Sinha C, Chinnaiyan AM (**mini symposium presentation**): An essential role for Argonaute 2 in EGFR-KRAS signaling in pancreatic cancer development, The AACR Annual Meeting, Chicago, IL, *Cancer Res*, 78, 13 Suppl, Abstr Nr 3020, 2018.
41. Zeinali M, Murlidhar V, Fouladdel S, Hafner M, Shao S, Zhao L, Cameron H, Bankhead AL, **Shi J**, Cuneo KC, Sahai V, Azizi E, Wicha MS, Simeone DM, Nagrath S (**poster presentation**): Increased number of EMT-like CTCs relative to epithelial CTCs reveals signatures of poor outcomes in pancreatic cancer, The AACR Annual Meeting, Chicago, IL, *Cancer Res*, 78, 13 Suppl, Abstr Nr 5579, 2018.
42. Ettel M, Zhao L, Schechter S, **Shi J** (**poster presentation**): Expression and prognostic value of NSD1 and SETD2 in pancreatic ductal adenocarcinoma and its precursor lesions, The USCAP Annual Meeting, Vancouver, BC, 2018.
43. Kim HS, Lu S, Cao Y, Yi Z, Jeyarajan S, Zhao L, Bedi K, Narayanan IV, Paulsen M, Ljungman M, **Shi J** (**poster presentation**): KMT2D mediates TGF- $\beta$ -induced epithelial-to-mesenchymal transition to promote more aggressive pancreatic cancer, AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care, Boston, MA, 2019.
44. Jeyarajan S, Yi Z, Wei S, Lu S, Kim H, Paulsen M, Bedi K, Ljungman M, **Shi J** (**poster presentation**): Loss of KDM6A promotes pancreatic cancer progression by upregulating epithelial-mesenchymal transition pathway, AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care, Boston, MA, 2019.



45. Fang J, **Shi J**: A Rare Papilocystic Variant of Acinar Cell Carcinoma in the Pancreas, College of American Pathologists 2019 Annual Meeting, Kissimmee, Florida, *Archives of Pathology & Laboratory Medicine*, 143, e2-e226, 2019.
46. Conner J, Aslam A, Sahai V, **Shi J**, Wasnik A, Mendiratta-Lala M (**platform and poster presentation**): Intraductal papillary neoplasm of the bile duct: radiology-pathology correlation, SCBT-MR Annual Meeting, Denver, CO, 2019.
47. Bhattarai S, Graham R, Sigel C, **Shi J**, Gonzalez RS, Xue Y, Krasinskas AM, HooKim K, Reid MD (**poster presentation**): Biliary tract involvement by hepatocellular carcinoma (HCC): an under-appreciated phenomenon and potential diagnostic pitfall in the evaluation of bile duct brushings, The USCAP Annual Meeting, National Harbor, MD, 2019.
48. Reid MD, Bhattarai S, Graham R, Pehlivanoglu B, Sigel C, **Shi J**, Saqi A, Shirazi M, Xue Y, Basturk O, Adsay NV (**platform presentation**): Fine needle aspiration findings in pancreatoblastoma (PBL): an analysis of 10 cases reveals helpful cytologic criteria in their distinction from common mimics, The USCAP Annual Meeting, National Harbor, MD, 2019.
49. Waters RE, McHugh KE, Fang J, Gu D, Lu H, **Shi J**, Downs-Kelly E, Roopkumar J, Sohal D, Allende D (**poster presentation**): Post-neoadjuvant pancreatic ductal adenocarcinoma: tumor burden, not tumor size, may predict outcome, The USCAP Annual Meeting, National Harbor, MD, 2019.
50. Aslam A, Mendiratta-Lala M, **Shi J**, Sahai V, Wasnik AP (**Scientific electronic exhibit**): Intraductal papillary neoplasm of the bile duct (IPNB): CT and MRI appearance with radiology-pathology correlation, 120th Annual Meeting of the ARRS, Chicago, IL, 2020.
51. Fang JM\*, Styles C\*, Zhao L, **Shi J** (\*Both authors contributed equally to this study): Impact of Whipple Grossing Method on Tumor Size, Lymph Node Yield, Margin, and Staging, USCAP 109th Annual Meeting, Los Angeles, 2020.
52. Hu J, Zhao M, Sarwate MM, Lu h, Lee G, Dhall D, Hale K, Matsuda Y, Suzuki Y, Okano K, **Shi J**, Fang j, Perry WR, Deshpande V, Pankaj A, Esposito I, Haeberle L, White R, Lowy A, Allende D, Hosseini-Varnamkhasi M (**platform presentation**): An International Retrospective Cohort Analysis of Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Therapy: Validation of the AJCC 8th Staging System and Tumor Response Scoring System, USCAP 110th Annual Meeting, Virtual, 2021.